Source comparison
Top Ipamorelin Studies: Research Comparison
Gobburu et al. (2004), Eur J Endocrinol Healthy adults (n=24) 200mcg SC, single dose Peak GH response 7.5-fold vs baseline None reported Svensson et al. (2006), Growth Horm IGF Res Rodent model 200mcg/kg BID, 28 days Lean mass & fat loss 30–50% sustained Minim
This comparison does not assign a generated winner or score.
- Gobburu et al. (2004), Eur J Endocrinol
- Healthy adults (n=24)
- 200mcg SC, single dose
- Peak GH response
- 7.5-fold vs baseline
- None reported
- Svensson et al. (2006), Growth Horm IGF Res
- Rodent model
- 200mcg/kg BID, 28 days
- Lean mass & fat loss
- 30–50% sustained
- Minimal
- Nedergaard et al. (2009), J Clin Endocrinol Metab
- GH-deficient adults (n=6)
- 200mcg SC TID, 12 weeks
- Lean mass gain
- Not measured directly
- Injection site reactions (mild)
- Johansen et al. (2010), J Bone Miner Res
- Postmenopausal women (n=42)
- 200mcg SC BID, 24 weeks
- Bone mineral density
- 4.7% lumbar BMD increase
- Transient hyperglycemia (8% of subjects)
- Clemmons et al. (2012), Am J Vet Res
- Equine tendon injury model
- 150mcg/kg BID, 8 weeks
- Tendon fiber realignment
- 40% faster recovery
- None